FDA approves Sepracor's metered-dose inhaler
MARLBOROUGH, Mass. -- The FDA in March approved Sepracor's New Drug application for Xopenex HFA Inhalation Aerosol, a metered-dose inhaler for the treatment of asthma and COPD. Xopenex is currently available for use in a nebulizer, but Sepracor plans to launch the metered-dose inhaler version around the end of the year. "We expect that the Xopenex HFA MDI will make Xopenex available to the large number of adult and children asthmatics who prefer the convenience of an MDI as part of their therapy," said Mark Corrigan, executive vice president of research and development at Sepracor.